Breaking News Instant updates and real-time market news.

TGTX

TG Therapeutics

$7.02

0.045 (0.65%)

07:37
09/12/19
09/12
07:37
09/12/19
07:37

TG Therapeutics presents ublituximab data at ECTRIMS Congress

TG Therapeutics presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company's novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis. The following summarizes the highlights from each presentation during the 35th ECTRIMS meeting: Title: Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis. This presentation includes the study design and demographic data from ULTIMATE I & II, two identical, randomized, international, multi-center, double-blinded, double dummy, active controlled Phase 3 trials, evaluating a twice per year one-hour 450mg infusion of ublituximab in RMS. These trials are being conducted under Special Protocol Assessment agreement with the U.S. Food and Drug Administration and are being led by Lawrence Steinman, MD, of Stanford University. Presentation Highlights: Patient recruitment for ULTIMATE I & II was successfully completed in the second half of 2018. Baseline characteristics of patients enrolled in ULTIMATE I & II are consistent with a typical RMS population. The ULTIMATE I & II trials are expected to elucidate the therapeutic potential of a one hour, 450mg infusion of ublituximab in patients with RMS. Topline results are expected in the second half of 2020. Title: Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis. This presentation includes long-term follow-up data for 45 patients from the Phase 2 trial that enrolled into the Open Label Extension trial and recaps the final efficacy data on patients enrolled in the Phase 2 study through 48 weeks of treatment. Presentation Highlights: Ublituximab continues to be well tolerated, with a median duration of follow-up of 124.7 weeks. No subjects discontinued due to an Adverse Event related to ublituximab on the Phase 2 or during the OLE. AEs deemed at least possibly related to ublituximab were infrequent during the OLE with all patients dosed at 450mg of ublituximab administered in a one-hour infusion. Infusion Related Reactions were rare during the OLE, occurring in only 5 patients, all Grade 1 or 2. An Annualized Relapse Rate of 0.07 was observed with 93% of subjects relapse free at Week 48.

TGTX TG Therapeutics
$7.02

0.045 (0.65%)

03/05/19
RHCO
03/05/19
NO CHANGE
Target $15
RHCO
Buy
TG Therapeutics price target lowered to $15 from $24 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on TG Therapeutics to $15, saying he has updated his model on the company's Marginal zone lymphoma readouts and the Follicular lymphoma data with new timing estimates for catalysts in those programs. The analyst also keeps his Buy rating on the shares longer term, saying he remains positive on TG Therapeutics' "capital-efficient strategy of utilizing therapeutics to develop novel combination therapies" and sees its proprietary doublet TG-1101 + TGR-1202 potentially serving patients across all lines of Chronic Lymphocytic Leukemia.
03/29/19
CANT
03/29/19
INITIATION
Target $17
CANT
Overweight
TG Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young initiated TG Therapeutics with an Overweight and $17 price target.
03/29/19
CANT
03/29/19
INITIATION
Target $17
CANT
Overweight
Cantor starts TG Therapeutics with Overweight rating, $17 price target
Cantor Fitzgerald analyst Alethia Young initiated coverage of TG Therapeutics with an Overweight rating and $17 price target. The analyst believes umbralisib and ublituximab have attractive profiles in oncology and autoimmune B-cell diseases. Investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis due to the competitive yet price sensitive landscape, but both lead assets as clinically de-risked with proven targets, Young tells investors in a research note. She thinks the risk/reward on TG shares is positive.
04/12/19
HCWC
04/12/19
NO CHANGE
Target $20
HCWC
Buy
TG granted orphan status for three lymphoma indications, says H.C. Wainwright
The FDA granted TG Therapeutics' umbralisib orphan drug status for three lymphoma indications, H.C. Wainwright analyst Edward White tells investors in a research note. The analyst continues to believe umbralisib will be launched in 2021, generating sales of $10.6M, growing to $141.5M in 2027. He keeps a Buy rating on TG Therapeutics with a $20 price target.

TODAY'S FREE FLY STORIES

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated  »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

LLY

Eli Lilly

$108.37

1.54 (1.44%)

14:15
10/13/19
10/13
14:15
10/13/19
14:15
Hot Stocks
Eli Lilly says Taltz met co-primary endpoints in Phase 3 plaque psoriasis study »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PCG

PG&E

$8.08

0.3 (3.86%)

07:46
10/13/19
10/13
07:46
10/13/19
07:46
Hot Stocks
PG&E says all customers impacted by safety shutoffs now have power »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

BNTX

BioNTech

$13.50

-0.85 (-5.92%)

, VIR

Vir Biotechnology

$14.06

(0.00%)

07:18
10/13/19
10/13
07:18
10/13/19
07:18
On The Fly
Opening Day: BioNTech raises $150M in smaller than expected IPO »

BioNTech (BNTX) raised…

BNTX

BioNTech

$13.50

-0.85 (-5.92%)

VIR

Vir Biotechnology

$14.06

(0.00%)

HBT

HBT Financial

$15.56

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

KRAT

Karat Packaging

$0.00

(0.00%)

POST

Post Holdings

$101.19

1.94 (1.95%)

IPHA

Innate Pharma

$0.00

(0.00%)

BRBR

BellRing Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 17

    Oct

  • 17

    Oct

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

, BAYRY

Bayer

$0.00

(0.00%)

04:55
10/13/19
10/13
04:55
10/13/19
04:55
Conference/Events
Healthcare Made Practical to hold a symposium »

Symposium on Clinical…

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

BAYRY

Bayer

$0.00

(0.00%)

BSX

Boston Scientific

$38.22

0.22 (0.58%)

BTG

B2Gold

$3.25

-0.2 (-5.80%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

LLY

Eli Lilly

$108.37

1.54 (1.44%)

MDT

Medtronic

$107.61

0.24 (0.22%)

PFE

Pfizer

$36.11

0.31 (0.87%)

PHG

Philips

$42.88

0.99 (2.36%)

TRUMY

Terumo

$0.00

(0.00%)

VAR

Varian Medical

$110.78

1.84 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 13

    Nov

AMBA

Ambarella

$53.62

1.25 (2.39%)

, ON

ON Semiconductor

$18.74

0.67 (3.71%)

09:31
10/12/19
10/12
09:31
10/12/19
09:31
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AMBA

Ambarella

$53.62

1.25 (2.39%)

ON

ON Semiconductor

$18.74

0.67 (3.71%)

AAPL

Apple

$236.21

6.12 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 28

    Oct

  • 30

    Oct

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

, AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

08:48
10/12/19
10/12
08:48
10/12/19
08:48
Periodicals
Bed Bath & Beyond not a bargain, Barron's says »

While Bed Bath &…

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

SNE

Sony

$58.16

0.83 (1.45%)

, MSFT

Microsoft

$139.62

0.52 (0.37%)

08:39
10/12/19
10/12
08:39
10/12/19
08:39
Periodicals
Activision, Take-Two to benefit from next videogame cycle, Barron's says »

Sony (SNE) has announced…

SNE

Sony

$58.16

0.83 (1.45%)

MSFT

Microsoft

$139.62

0.52 (0.37%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 21

    Nov

  • 21

    Nov

K

Kellogg

$62.14

-0.27 (-0.43%)

08:27
10/12/19
10/12
08:27
10/12/19
08:27
Periodicals
Kellogg stock looking like worth 'snacking on,' Barron's says »

Kellogg's stock fell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

, ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

08:20
10/12/19
10/12
08:20
10/12/19
08:20
Periodicals
J&J, Pentair among stocks with sage, growing dividends, Barron's says »

Investors seeking yield…

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

, BAYRY

Bayer

$0.00

(0.00%)

04:55
10/12/19
10/12
04:55
10/12/19
04:55
Conference/Events
Healthcare Made Practical to hold a symposium »

Symposium on Clinical…

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

BAYRY

Bayer

$0.00

(0.00%)

BSX

Boston Scientific

$38.22

0.22 (0.58%)

BTG

B2Gold

$3.25

-0.2 (-5.80%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

LLY

Eli Lilly

$108.37

1.54 (1.44%)

MDT

Medtronic

$107.61

0.24 (0.22%)

PFE

Pfizer

$36.11

0.31 (0.87%)

PHG

Philips

$42.88

0.99 (2.36%)

TRUMY

Terumo

$0.00

(0.00%)

VAR

Varian Medical

$110.78

1.84 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.